SCHEMBL2377482

SCHEMBL2377482

O=S(=O)(Cc1ccccc1OC(F)F)C(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 1/20 0.41
SLC6A2 P23975 4/20 0.39
SLC6A4 P31645 4/20 0.39
KCNH2 Q12809 4/20 0.39
SLC6A3 Q01959 3/20 0.39
CYP2D6 P10635 1/20 0.39
KMT2A Q03164 1/20 0.39
SLC22A12 Q96S37 1/20 0.38
DRD1 P21728 1/20 0.37
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36
RORC P51449 1/20 0.35
TACR1 P25103 1/20 0.35
ALKBH1 Q13686 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
POLB P06746 1/20 0.35
PTGES2 Q9H7Z7 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9530973 0.83 TNF (0.44) TNFSLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL1271302 0.83 TNF (0.41) TNFSLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL1271303 0.83 TNF (0.44) TNFSLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL5696557 0.81 TNF (0.43) TNFSLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL1272037 0.80 KMT2A (0.40) TNFSLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL14426917 0.78 TNF (0.40) TNFSLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL2650387 0.76 TNF (0.49) TNFSLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL3366569 0.76 TNF (0.49) TNFSLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL6630648 0.74 KMT2A (0.65) TNFSLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL9844357 0.73 TNF (0.39) TNFSLC6A2SLC6A4KCNH2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8013183-B2 Alpha ketoamide compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2011-09-06 US disclosed
US-20100305331-A1 ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY, INC. (US) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305331-A1 ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS CTSS, CTSF, CTSB TNF 1900/4885SLC6A2 3653/4885SLC6A4 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.